“We are poised for another year of record financial results in 2026. For the full year, we expect to see revenue exceed $110 million and at least a 30% Adjusted EBITDA margin,” concluded Brynjelsen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Is ETON a Buy, Before Earnings?
- Eton Pharmaceuticals participates in a conference call with Craig-Hallum
- Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum
- Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
- Eton in-licenses U.S. commercialization rights to HEMANGEOL from Pierre Fabre